专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007037849A3 COMPOSITIONS AND METHODS FOR THE INTRAOCULAR TRANSPORT OF THERAPEUTIC AGENTS 审中-公开
标题翻译：治疗药物内分泌运输的组合物和方法
公开(公告)号：WO2007037849A3
公开(公告)日：2008-01-24
申请号：PCT/US2006032765
申请日：2006-08-23
申请人： ALLERGAN INC , HUGHES PATRICK M , OLEJNIK OREST , CHANG-LIN JOAN-EN
发明人： HUGHES PATRICK M , OLEJNIK OREST , CHANG-LIN JOAN-EN
IPC分类号： A61K47/48
CPC分类号： A61K31/557 , A61K9/0048 , A61K31/498 , A61K31/513 , A61K47/542 , A61K47/549 , A61K47/55 , A61K47/551 , A61K47/64
摘要： Membrane transporter-targeted therapeutic agents and methods of making and using the same.
摘要翻译：膜转运体靶向治疗剂及其制备和使用方法。

2. 发明申请

WO2006122165A3 OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR AGONISTS HAVING ENHANCED ANTERIOR CLEARANCE RATES 审中-公开
标题翻译：使用具有增强的前列腺增生率的ALPHA-2 ADRENERGIC受体激动剂进行的OCULAR治疗
公开(公告)号：WO2006122165A3
公开(公告)日：2007-05-31
申请号：PCT/US2006018019
申请日：2006-05-09
申请人： ALLERGAN INC , HUGHES PATRIC M , BURKE JAMES A , CHANG-LIN JOAN-EN
发明人： HUGHES PATRIC M , BURKE JAMES A , CHANG-LIN JOAN-EN
IPC分类号： A61K9/00
CPC分类号： A61K9/0051 , A61K9/0048 , A61K9/1647
摘要： Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye to which the material is administered. The alpha 2 adrenergic receptor agonist may have a vitreal half-life greater than about three hours. The present materials are effective in treating an ocular condition(s) that affect the anterior segment of an eye, or the anterior and posterior segment of the eye. The materials are suitable for intravitreal or periocular administration and can provide prolonged drug delivery and therapeutic benefits to patients to which the materials have been administered. The alpha 2 adrenergic receptor agonists can be provided in liquid-containing formulations and/or bioerodible and/or non-bioerodible polymeric implants and microparticles. Methods of making and using the present materials are also described.
摘要翻译：眼科治疗材料，例如含液组合物和聚合物药物递送系统，包括治疗成分，其包括α2肾上腺素能受体激动剂，其从施用该物质的个体眼睛的前段清除。 α2肾上腺素能受体激动剂可具有大于约3小时的玻璃体半衰期。本发明的材料可有效治疗影响眼前段或眼部前段和后段的眼睛状况。这些材料适用于玻璃体内或眼周内给药，并且可以为已经施用材料的患者提供延长的药物递送和治疗益处。 α2肾上腺素能受体激动剂可以在含液制剂和/或生物可侵蚀和/或非生物可侵蚀的聚合物植入物和微粒中提供。还描述了制备和使用本发明材料的方法。

3. 发明申请

WO2005105067A2 DRUG DELIVERY TO THE BACK OF THE EYE 审中-公开
标题翻译：药物递送到眼睛的背面
公开(公告)号：WO2005105067A2
公开(公告)日：2005-11-10
申请号：PCT/US2005/011960
申请日：2005-04-11
申请人： ALLERGAN, INC. , LYONS, Robert, T. , CHANG, Chin-Ming , CHANG-LIN, Joan-En , CHANG, James , OLEJNIK, Orest
发明人： LYONS, Robert, T. , CHANG, Chin-Ming , CHANG-LIN, Joan-En , CHANG, James , OLEJNIK, Orest
IPC分类号： A61K31/00
CPC分类号： A61K9/0014 , A61K9/0048 , A61K31/57 , A61K31/573 , A61K31/724 , A61K47/38 , A61K47/40
摘要： Disclosed herein are methods of delivering drugs or therapeutically active agents to the back of the eye via topical administration of compositions comprising cyclodextrin derivatives. Compositions related thereto are also disclosed herein.
摘要翻译：本文公开了通过局部施用包含环糊精衍生物的组合物将药物或治疗活性剂递送至眼睛后部的方法。本文还公开了与其相关的组合物。

4. 发明申请

WO2006104760A3 OPHTHALMIC COMPOSITIONS COMPRISING dDC 审中-公开
公开(公告)号：WO2006104760A3
公开(公告)日：2006-10-05
申请号：PCT/US2006/010176
申请日：2006-03-21
申请人： ALLERGAN, INC. , HUGHES, Patrick, M. , SCHIFFMAN, Rhett, M. , JENSEN, Harold, G. , CHANG-LIN, Joan-En
发明人： HUGHES, Patrick, M. , SCHIFFMAN, Rhett, M. , JENSEN, Harold, G. , CHANG-LIN, Joan-En
IPC分类号： A61K31/7068 , A61K9/00 , A61P27/02
摘要： A composition comprising dDC and a polymer, wherein the composition is an aqueous liquid with a viscosity which increases upon contact with a surface of an eye is disclosed herein. An aqueous composition comprising a therapeutically effective concentration of dDC, wherein the concentration of dDC is less than 1% is also disclosed. An eye drop comprising a therapeutically effective amount of dDC, wherein the amount of dDC is less than 300 μg is also disclosed. A method comprising administering an effective amount of dDC topically to an eye of a person suffering from viral conjunctivitis a viral infection, wherein less than 300 μL of dDC is administered to said eye is also disclosed. A kit comprising a composition and a dispenser, wherein said dispenser dispenses a drop comprising a therapeutically effective amount of dDC, wherein the amount of dDC is less than 300 μg is also disclosed.

5. 发明申请

WO2006055454A2 OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES 审中-公开
标题翻译：眼科组合物和治疗眼睛的方法
公开(公告)号：WO2006055454A2
公开(公告)日：2006-05-26
申请号：PCT/US2005041064
申请日：2005-11-14
申请人： ALLERGAN INC , VEHIGE JOSEPH G , SIMMONS PETER A , CHANG-LIN JOAN-EN
发明人： VEHIGE JOSEPH G , SIMMONS PETER A , CHANG-LIN JOAN-EN
CPC分类号： A61K31/205 , A61K9/0048 , A61K9/08 , A61K31/047 , A61K31/14 , A61K31/70 , A61K31/717 , A61K31/728 , A61K38/1732 , A61K47/02 , A61K47/26 , A61K47/38
摘要： Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
摘要翻译：包括相容性溶质组分和/或聚阴离子组分的眼科组合物可用于治疗眼睛，例如用于缓解干眼症，保护眼睛免受高渗损伤和/或阳离子物质对眼睛和/ 或促进从眼科手术恢复。

6. 发明申请

WO2005107706A3 BIODEGRADABLE INTRAVITREAL TYROSINE KINASE INHIBITORS IMPLANTS 审中-公开
标题翻译：可生物降解的侵袭性酪氨酸激酶抑制剂植入物
公开(公告)号：WO2005107706A3
公开(公告)日：2006-01-12
申请号：PCT/US2005014649
申请日：2005-04-27
申请人： ALLERGAN INC , HUGHES PATRICK M , MALONE THOMAS , DEVRIES GERALD , EDELMAN JEFFREY L , CHANG-LIN JOAN-EN , SHIAH JANE GUO , NAVAGGLIOLI THIERRY , SPADA LON T , BLANDA WENDY M
发明人： HUGHES PATRICK M , MALONE THOMAS , DEVRIES GERALD , EDELMAN JEFFREY L , CHANG-LIN JOAN-EN , SHIAH JANE GUO , NAVAGGLIOLI THIERRY , SPADA LON T , BLANDA WENDY M
IPC分类号： A61K9/00 , A61K9/20 , A61K31/00 , A61K31/404
CPC分类号： A61K9/0051 , A61K9/1647 , Y10T428/2985
摘要： Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
摘要翻译：生物相容性眼内植入物包括酪氨酸激酶抑制剂和可生物降解的聚合物，其有效促进酪氨酸激酶抑制剂延长一段时间的眼睛玻璃体。植入物的治疗剂可以与可生物降解的聚合物基质相关，例如基本上不含聚乙烯醇的基质。植入物可以放置在眼睛中以治疗或减少一种或多种眼部病症的发生。

7. 发明申请

WO2007037849A2 COMPOSITIONS AND METHODS FOR THE INTRAOCULAR TRANSPORT OF THERAPEUTIC AGENTS 审中-公开
标题翻译：治疗药物内分泌运输的组合物和方法
公开(公告)号：WO2007037849A2
公开(公告)日：2007-04-05
申请号：PCT/US2006/032765
申请日：2006-08-23
申请人： ALLERGAN, INC. , HUGHES, Patrick, M. , OLEJNIK, Orest , CHANG-LIN, Joan-en
发明人： HUGHES, Patrick, M. , OLEJNIK, Orest , CHANG-LIN, Joan-en
IPC分类号： A61K47/48
CPC分类号： A61K31/557 , A61K9/0048 , A61K31/498 , A61K31/513 , A61K47/542 , A61K47/549 , A61K47/55 , A61K47/551 , A61K47/64
摘要： Membrane transporter-targeted therapeutic agents and methods of making and using the same.
摘要翻译：膜转运体靶向治疗剂及其制备和使用方法。

8. 发明申请

WO2006122165A2 OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR AGONISTS HAVING ENHANCED ANTERIOR CLEARANCE RATES 审中-公开
标题翻译：使用具有增强的前列腺增生率的ALPHA-2 ADRENERGIC受体激动剂进行的OCULAR治疗
公开(公告)号：WO2006122165A2
公开(公告)日：2006-11-16
申请号：PCT/US2006/018019
申请日：2006-05-09
申请人： ALLERGAN, INC. , HUGHES, Patric, M. , BURKE, James, A. , CHANG-LIN, Joan-En
发明人： HUGHES, Patric, M. , BURKE, James, A. , CHANG-LIN, Joan-En
CPC分类号： A61K9/0051 , A61K9/0048 , A61K9/1647
摘要： Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye to which the material is administered. The alpha 2 adrenergic receptor agonist may have a vitreal half-life greater than about three hours. The present materials are effective in treating an ocular condition(s) that affect the anterior segment of an eye, or the anterior and posterior segment of the eye. The materials are suitable for intravitreal or periocular administration and can provide prolonged drug delivery and therapeutic benefits to patients to which the materials have been administered. The alpha 2 adrenergic receptor agonists can be provided in liquid-containing formulations and/or bioerodible and/or non-bioerodible polymeric implants and microparticles. Methods of making and using the present materials are also described.
摘要翻译：眼科治疗材料，例如含液组合物和聚合物药物递送系统，包括治疗成分，其包括α2肾上腺素能受体激动剂，其从施用该物质的个体眼睛的前段清除。 α2肾上腺素能受体激动剂可具有大于约3小时的玻璃体半衰期。本发明的材料可有效治疗影响眼前段或眼部前段和后段的眼睛状况。这些材料适用于玻璃体内或眼周内给药，并且可以为已经施用材料的患者提供延长的药物递送和治疗益处。 α2肾上腺素能受体激动剂可以在含液制剂和/或生物可侵蚀和/或非生物可侵蚀的聚合物植入物和微粒中提供。还描述了制备和使用本发明材料的方法。

9. 发明申请

WO2006104760A2 OPHTHALMIC COMPOSITIONS COMPRISING dDC 审中-公开
标题翻译：包含dDC的透明组合物
公开(公告)号：WO2006104760A2
公开(公告)日：2006-10-05
申请号：PCT/US2006010176
申请日：2006-03-21
申请人： ALLERGAN INC , HUGHES PATRICK M , SCHIFFMAN RHETT M , JENSEN HAROLD G , CHANG-LIN JOAN-EN
发明人： HUGHES PATRICK M , SCHIFFMAN RHETT M , JENSEN HAROLD G , CHANG-LIN JOAN-EN
CPC分类号： A61K9/0048 , A61K31/7068
摘要： A composition comprising dDC and a polymer, wherein the composition is an aqueous liquid with a viscosity which increases upon contact with a surface of an eye is disclosed herein. An aqueous composition comprising a therapeutically effective concentration of dDC, wherein the concentration of dDC is less than 1% is also disclosed. An eye drop comprising a therapeutically effective amount of dDC, wherein the amount of dDC is less than 300 µg is also disclosed. A method comprising administering an effective amount of dDC topically to an eye of a person suffering from viral conjunctivitis a viral infection, wherein less than 300 µL of dDC is administered to said eye is also disclosed. A kit comprising a composition and a dispenser, wherein said dispenser dispenses a drop comprising a therapeutically effective amount of dDC, wherein the amount of dDC is less than 300 µg is also disclosed.
摘要翻译：包含dDC和聚合物的组合物，其中所述组合物是具有在与眼表面接触时增加的粘度的水性液体。还公开了包含治疗有效浓度的dDC的水性组合物，其中dDC的浓度小于1％。还公开了包含治疗有效量的dDC的滴眼剂，其中dDC的量小于300μg。还公开了一种将有效量的dDC局部施用于患有病毒性结膜炎的人的眼睛的病毒感染的方法，其中向所述眼睛施用小于300μL的dDC。一种包含组合物和分配器的试剂盒，其中所述分配器分配包含治疗有效量的dDC的液滴，其中dDC的量小于300μg也被公开。

10. 发明申请

WO2005105067A3 AQUEOUS SOLUTIONS COMPRISING PREDNISOLONE AND A CYCLODEXTRIN DERIVATIVE 审中-公开
标题翻译：包含PREDNISOLONE和CYCLODEXTRIN DERIVATIVE的水溶液
公开(公告)号：WO2005105067A3
公开(公告)日：2006-04-27
申请号：PCT/US2005011960
申请日：2005-04-11
申请人： ALLERGAN INC , LYONS ROBERT T , CHANG CHIN-MING , CHANG-LIN JOAN-EN , CHANG JAMES , OLEJNIK OREST
发明人： LYONS ROBERT T , CHANG CHIN-MING , CHANG-LIN JOAN-EN , CHANG JAMES , OLEJNIK OREST
IPC分类号： A61K9/00 , A61K31/00 , A61K31/57 , A61K31/573 , A61K31/724 , A61K47/38 , A61K47/40 , A61K47/48 , A61P27/02
CPC分类号： A61K9/0014 , A61K9/0048 , A61K31/57 , A61K31/573 , A61K31/724 , A61K47/38 , A61K47/40
摘要： Disclosed herein are methods of delivering drugs or therapeutically active agents to the back of the eye via topical administration of compositions comprising cyclodextrin derivatives. Compositions related thereto are also disclosed herein.
摘要翻译：本文公开了通过局部施用包含环糊精衍生物的组合物将药物或治疗活性剂递送至眼睛后部的方法。本文还公开了与其相关的组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式